44. 多発血管炎性肉芽腫症 Wegener granulomatosis Clinical trials / Disease details

臨床試験数 : 92 / 薬物数 : 106 - (DrugBank : 27) / 標的遺伝子数 : 22 - 標的パスウェイ数 : 78

18 trials found

diseases per page:

Showing 1 to 10 of 18 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05263934 (ClinicalTrials.gov)	March 14, 2022	28/2/2022	Efficacy and Safety of Depemokimab Compared With Mepolizumabin Adults With Relapsing or Refractory E ...	A 52-week, Randomized, Double-blind, Double-dummy, Parallel-group, Multi-centre, Non-inferiority Stu ...	Eosinophilic Granulomatosis With Polyangiitis	Biological: Depemokimab;Biological: Mepolizumab;Drug: Placebo matching mepolizumab;Drug: Placebo mat ...	GlaxoSmithKline	NULL	Not yet recruiting	18 Years	N/A	All	160	Phase 3	NULL
2	NCT05030155 (ClinicalTrials.gov)	December 2021	31/7/2021	Study of Mepolizumab-based Regimen Compared to Conventional Therapeutic Strategy in Patients With Eo ...	Evaluation of MEpolizumab-based Regimen Compared to Conventional Therapeutic Strategy For Remission ...	Eosinophilic Granulomatosis With Polyangiitis	Drug: Mepolizumab;Drug: cyclophosphamide /azathioprine;Drug: Placebo	Assistance Publique - Hôpitaux de Paris	French Vasculitis Study Group;URC-CIC Paris Descartes Necker Cochin	Not yet recruiting	18 Years	N/A	All	100	Phase 3	France
3	EUCTR2019-001832-77-IT (EUCTR)	25/02/2020	15/06/2021	A study to evaluate if benralizumab compared to mepolizumabmay be beneficial in the treatment of Eos ...	A Randomized, Double-blind, Active-controlled 52-week Study with an Open-label Extension to Evaluate ...	Eosinophilic Granulomatosis with Polyangiitis (EGPA) MedDRA version: 20.1;Level: LLT;Classification ...	Trade Name: NUCALA Product Name: mepolizumab Product Code: [L04AC06] INN or Proposed INN: Mepolizumab Pr ...	ASTRAZENECA AB	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	140	Phase 3	France;United States;Canada;Belgium;Israel;Germany;United Kingdom;Japan;Italy
4	EUCTR2019-001832-77-DE (EUCTR)	15/01/2020	21/08/2019	Efficacy and Safety of Benralizumab in EGPA compared to mepolizumab.	A Randomized, Double-blind, Active-controlled 52-week Study with an Open-label Extension to Evaluate ...	Eosinophilic Granulomatosis with Polyangiitis (EGPA) MedDRA version: 20.1;Level: LLT;Classification ...	Trade Name: Fasenra Product Name: benralizumab Product Code: MEDI-563 INN or Proposed INN: benralizumab ...	AstraZeneca AB	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	140	Phase 3	France;United States;Canada;Belgium;Israel;Germany;United Kingdom;Italy;Japan
5	JPRN-JapicCTI-195049	24/12/2019	26/11/2019	MANDARA	A Randomized, Double-blind, Active-controlled 52-week Study With an Open-label Extension to Evaluate ...	Eosinophilic Granulomatous Vasculitis	Intervention name : Biological: Benralizumab, Biological: Placebo to Mepolizumab INN of the interven ...	AstraZeneca KK	NULL	recruiting	18		BOTH	6	Phase 3	Japan, North America, Europe
6	EUCTR2019-001832-77-FR (EUCTR)	23/12/2019	02/08/2019	A study to evaluate if benralizumab compared to mepolizumabmay be beneficial in the treatment of Eos ...	A Randomized, Double-blind, Active-controlled 52-week Study with an Open-label Extension to Evaluate ...	Eosinophilic Granulomatosis with Polyangiitis (EGPA);Therapeutic area: Diseases [C] - Respiratory Tr ...	Product Name: benralizumab Product Code: MEDI-563 INN or Proposed INN: benralizumab Other descriptive n ...	AstraZeneca AB	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	140	Phase 3	United States;France;Canada;Belgium;Israel;Germany;Japan;Italy;United Kingdom
7	NCT04157348 (ClinicalTrials.gov)	October 29, 2019	29/9/2019	Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab.	A Randomized, Double-blind, Active-controlled 52-week Study With an Open-label Extension to Evaluate ...	Eosinophilic Granulomatous Vasculitis	Biological: Benralizumab;Biological: Mepolizumab;Biological: Placebo to Mepolizumab;Biological: Plac ...	AstraZeneca	NULL	Recruiting	18 Years	130 Years	All	140	Phase 3	United States;Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom
8	EUCTR2019-001832-77-GB (EUCTR)	20/08/2019	22/10/2020	Efficacy and Safety of Benralizumab in EGPA compared to mepolizumab.	A Randomized, Double-blind, Active-controlled 52-week Study with an Open-label Extension to Evaluate ...	Eosinophilic Granulomatosis with Polyangiitis (EGPA);Therapeutic area: Diseases [C] - Respiratory Tr ...	Product Name: benralizumab Product Code: MEDI-563 INN or Proposed INN: benralizumab Other descriptive n ...	AstraZeneca AB	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	140	Phase 3	United States;France;Canada;Belgium;Israel;Germany;Japan;Italy;United Kingdom
9	EUCTR2014-003162-25-BE (EUCTR)	06/07/2015	01/06/2015	Mepolizumab Long-term Access Programme for Subjects who Participated in Study MEA115921	MepolizumabLong-term Access Programme for Subjects who Participated in Study MEA115921 (Placebo-cont ...	Eosinophilic Granulomatosis with Polyangiitis (formerly known as Churg-Strauss Syndrome) MedDRA vers ...	Product Name: SB-240563 (mepolizumab) Product Code: SB-240563 (mepolizumab) INN or Proposed INN: Mepol ...	GlaxoSmithKline Research Ltd	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	115	Phase 3	United States;Canada;Belgium;Germany;United Kingdom;Japan
10	NCT03298061 (ClinicalTrials.gov)	April 14, 2015	27/9/2017	Long-term Access Program (LAP) of Mepolizumab for Subjects Who Participated in Study MEA115921	MepolizumabLong-term Access Programme for Subjects Who Participated in Study MEA115921 (Placebo-cont ...	Churg-Strauss Syndrome	Drug: Mepolizumab;Drug: Prednisolone	GlaxoSmithKline	NULL	Active, not recruiting	18 Years	N/A	All	104	Phase 3	United States;Belgium;Canada;France;Germany;Japan;United Kingdom

First Previous1 2Next Last